Table 3.
Cause-specific mortality according to time since diagnosis of lymphoproliferative malignancy in individuals with and without celiac disease
| Deaths in CD vs. deaths in controls | Crude | Adjusted | |||
|---|---|---|---|---|---|
| Follow-up | HR | CI | HR | CI | |
| Any overall | 140 vs. 232 | 1.33 | (1.08–1.65) | 1.22 | (0.97–1.52) |
| Year 1 | 115 vs. 175 | 2.11 | (1.53–2.91) | 1.94 | (1.39–2.70) |
| Years 2–5 | 18 vs. 40 | 0.98 | (0.67–1.43) | 0.94 | (0.64–1.38) |
| Years >5 | 7 vs. 17 | 0.91 | (0.58–1.42) | 0.77 | (0.49–1.21) |
| NHL* overall | 108 vs. 113 | 1.35 | (1.03–1.75) | 1.23 | (0.93–1.62) |
| Year 1 | 95 vs. 91 | 1.90 | (1.31–2.76) | 1.67 | (1.13–2.47) |
| Years 2–5 | 10 vs. 15 | 1.08 | (0.64–1.80) | 1.02 | (0.60–1.72) |
| Years >5 | 3 vs. 7 | 0.77 | (0.42–1.39) | 0.74 | (0.40–1.36) |
| Non-NHL# overall | 32 vs. 119 | 1.40 | (0.95–2.08) | 1.24 | (0.82–1.87) |
| Year 1 | 20 vs. 84 | 1.56 | (0.73–3.33) | 1.35 | (0.63–2.88) |
| Years 2–5 | 8 vs. 25 | 1.25 | (0.68–2.28) | 1.05 | (0.56–1.95) |
| Years >5 | 4 vs. 10 | 1.53 | (0.76–3.08) | 1.51 | (0.71–3.24) |
HR, Hazard ratio; NHL, Non-Hodgkin lymphoma; HL, Hodgkin lymphoma, CLL, Chronic lymphatic leukemia; ALL, Acute lymphatic leukemia;
Non-NHL=Myeloma + Hodgkin lymphoma + Chronic lymphatic leukemia + Acute lymphatic leukemia.
*
For example, individuals with celiac disease + NHL were at increased risk (adjusted hazard ratio=1.23) to die from NHL compared with individuals with NHL only.
Adjustment, see methods for description